Aceclofenac is indicated for inflammatory musculoskeletal conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute injuries like sprains or strains. It is not intended for non-inflammatory pain such as tension-type headaches.
Pain relief usually begins within 30-60 minutes after oral intake, with the maximum effect occurring around 1-2 hours. This rapid onset makes it suitable for both chronic and acute inflammatory pain.
Concurrent use of two NSAIDs increases the risk of gastrointestinal bleeding and renal impairment. It is generally advised to avoid combining aceclofenac with other NSAIDs, including over-the-counter ibuprofen or aspirin, unless specifically instructed by a physician.
Aceclofenac is contraindicated in the third trimester because it may cause premature closure of the fetal ductus arteriosus. Use in the first or second trimester should only occur if the potential benefit justifies the risk and under close medical supervision.
Mild stomach discomfort is common and may improve with food. If pain becomes severe, is accompanied by vomiting blood, or you notice black stools, seek medical attention immediately as these could signal serious gastrointestinal bleeding.
Like other NSAIDs, aceclofenac can cause fluid retention and diminish the efficacy of antihypertensive drugs, potentially raising blood pressure. Regular monitoring is recommended for patients with hypertension.
Alcohol increases the risk of gastrointestinal irritation and bleeding when combined with NSAIDs. It is advisable to limit alcohol consumption while on aceclofenac.
Store the tablets at room temperature, away from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.
Other NSAIDs such as ibuprofen, naproxen, or selective COX-2 inhibitors (e.g., celecoxib) may be used, as well as non-NSAID options like paracetamol or disease-modifying antirheumatic drugs (DMARDs). Choice depends on individual risk factors and physician assessment.
Both belong to the same chemical family, but aceclofenac is considered to have a slightly better gastrointestinal safety profile due to its relative COX-2 selectivity. Clinical decisions should be based on efficacy, tolerance, and patient-specific considerations.
Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce inflammation. It belongs to the broader class of NSAIDs that work by inhibiting cyclo-oxygenase enzymes, which are key to the production of prostaglandins-molecules that promote pain, swelling, and fever. In the United Kingdom, aceclofenac is a prescription-only medicine regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as an oral pill in two strengths: 100 mg and 200 mg.
Aceclofenac blocks the activity of cyclo-oxygenase-2 (COX-2) more selectively than older NSAIDs, while still affecting COX-1 at higher doses. By reducing the synthesis of prostaglandins, the drug:
The onset of analgesia is typically within 30-60 minutes after oral administration, with peak plasma concentrations reached in about 1-2 hours. The drug’s half-life is approximately 4 hours, which supports a twice-daily dosing schedule for most adult indications.
Aceclofenac is approved in the UK for the following indications:
These uses reflect the drug’s ability to control both chronic inflammatory joint disease and short-term inflammatory pain.
Special attention is required for elderly patients, who are more prone to renal effects and gastrointestinal complications. Dose reductions or alternative therapies may be considered.
These effects are usually transient and may improve with food intake.
Patients should provide a complete list of all medicines, over-the-counter products, and herbal supplements to their prescriber to avoid unanticipated interactions.
Dose adjustments are recommended for:
If a dose is missed, take it as soon as remembered unless it is close to the time of the next scheduled dose. Do not double the dose to catch up.
Symptoms may include nausea, vomiting, abdominal pain, drowsiness, or gastrointestinal bleeding. In case of suspected overdose, seek emergency medical care or contact the UK National Poisons Information Service (NPIS).
Short-term therapy generally does not require tapering. For long-term use, the prescriber may advise a gradual reduction to monitor for rebound pain or inflammation.
While routine laboratory monitoring is not mandatory for short courses, the following assessments are advisable for chronic therapy:
Patients should report any new gastrointestinal symptoms, swelling, or unexplained fatigue promptly.
This article provides educational information about aceclofenac and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
